Specialty Pharmacy

Trial data shows positive results across a range of difficult-to-treat patients with MM.

Amy Grogg, PharmD, senior vice president of Strategy and Commercialization at AmerisourceBergen Specialty Group, discusses developing trends in specialty drug cost management.

Research may lead to gel that prevents transmission of HIV, hepatitis C and the Ebola virus.

HIMSS is working to determine the readiness of providers to participate in the types of value-based payment models that CMS is moving toward.

Researchers examine impact of probiotics on inflammatory bowel disease.

XSTAT 30 is typically used to control life-threatening bleeding in military settings.

A pharmacy must pay $60,000 in a settlement resolving allegations that it violated the Controlled Substances Act and the Combat Methamphetamine Epidemic Act of 2005.

An HCV vaccine, while elusive, offers the best hope to eradicate the virus.

Top news of the week in cancer drug development.

Eating before bed can have a significant impact on the development of nonalcoholic fatty liver disease.

Researchers consider the ramifications of using organs from infected patients to save lives.

Liver damage caused by hepatitis C may eventually be overcome through stem cell therapy.

Researchers target effect of various medical conditions on platelet function.

New treatment option for patients who no longer respond to Xalkori.

Enhanced screening and treatment in high-risk populations could eliminate virus.

Top stories of the week on Specialty Pharmacy Times.

Researchers target how cancer cells avoid treatment.

Clean needle programs have reduced HIV incidence among injection drug abusers by 80% from 1990 to 2006.

Shopping around carefully for plans will be important for Medicare Part D enrollees.

Through a voluntary field safety notification, Insulet Corporation is notifying consumers and health care professionals about a slight increase in reports in which the OmniPod's needle mechanism to deliver insulin fails to deploy or is delayed.

Asthma may increase the likelihood of chronic migraines in patients with episodic migraines.

CMS report shows spending rates are lower compared with the years prior to health care reform.

Treatment shows clinically meaningful reduction in the number of cancer cells in patients with relapsed or refractory chronic lymphocytic leukemia.

MS patients with visual problems perform worse in testing than patients without visual problems but with MS.

Higher number of unprotected sexual encounters correlates with enhanced cell expressions.

Early treatment found to be cost-effective compared with waiting until liver fibrosis worsens.

Overall survival rate nearly doubles in patients who used aspirin post-diagnosis.

Addition of midostaurin to chemotherapy shows promise in patients with AML.

Successful response to hepatitis C treatment shows a 30 percent increased reduction in liver stiffness.

Majority of hemophilia patients show problems with mobility, daily activities, and pain.